ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Coronavirus COVID-19 Update: Hydroxychloroquine and Other Treatments
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 175824" data-attributes="member: 3"><p>When we have the antibody test available. It got approved two weeks ago. Here is how antibodies develop. The question is how long IgG will last.</p><p>[ATTACH=full]9522[/ATTACH]</p><p></p><p></p><p><strong>Cellex Receives First FDA Emergency Use Authorization for Coronavirus Serology Test</strong></p><p>Apr 02, 2020 </p><p> </p><p>NEW YORK – On Wednesday, Cellex became the first firm to receive Emergency Use Authorization from the US Food and Drug Administration for a coronavirus serology test. The assay, which resembles a pregnancy test, is authorized for use in laboratories certified under CLIA to perform as moderate- and highly-complexity tests.</p><p></p><p>Called the qSARS-CoV-2 IgG/IgM Rapid Test, the Cellex test is a lateral flow immunoassay to detect IgG and IgM in blood serum, plasma, or venipuncture whole blood specimens from patients suspected by a healthcare provider of COVID-19 infection. Results can be read from the test device after approximately 15 minutes according to the instructions for use, and labs must report positive results to public health authorities.</p><p></p><p>The levels of IgM in a patient's blood begin to rise to detectable levels a few days after infection, while IgG levels become elevated later. Positive results for both IgG and IgM could occur after infection and be indicative of acute or recent infection.</p><p></p><p>The FDA has guided in its "Policy D" that serology tests that are not intended for sole diagnosis do not need only to notify the agency prior to marketing in the US and do not need to come through the EUA process. However, it has also guided that manufacturers claiming a test can be used as a sole diagnostic should come submit an EUA.</p><p></p><p>The test's clinical validation, as noted in the IFU, involved 98 positive serum or plasma samples collected from individuals who tested positive with a RT- PCR method for SARS-CoV-2 infection who exhibited mild or no clinical symptoms and 180 negative serum or plasma samples collected prior to September 2019.</p><p></p><p>Of the 98 positive samples, 91 were positive with IgG or IgM or both. Of the 180 negative samples, 174 were negative.</p><p></p><p>Another 30 samples were collected from hospitalized individuals who were clinically confirmed positive for SARSCoV-2 infection and exhibited severe symptoms. These samples, along with 70 negative serum or plasma samples, were tested with the qSARS-CoV-2 IgG/IgM Rapid Test. Of the 30 positive samples, 29 were positive with IgG or IgM or both. Of the 70 negative samples, 65 were negative.</p><p></p><p>Taken together, the qSARS-CoV-2 IgG/IgM Rapid Test had a 94 percent positive percent agreement and 96 percent negative percent agreement.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 175824, member: 3"] When we have the antibody test available. It got approved two weeks ago. Here is how antibodies develop. The question is how long IgG will last. [ATTACH type="full" alt="covid19 antibodies.jpg"]9522[/ATTACH] [B]Cellex Receives First FDA Emergency Use Authorization for Coronavirus Serology Test[/B] Apr 02, 2020 NEW YORK – On Wednesday, Cellex became the first firm to receive Emergency Use Authorization from the US Food and Drug Administration for a coronavirus serology test. The assay, which resembles a pregnancy test, is authorized for use in laboratories certified under CLIA to perform as moderate- and highly-complexity tests. Called the qSARS-CoV-2 IgG/IgM Rapid Test, the Cellex test is a lateral flow immunoassay to detect IgG and IgM in blood serum, plasma, or venipuncture whole blood specimens from patients suspected by a healthcare provider of COVID-19 infection. Results can be read from the test device after approximately 15 minutes according to the instructions for use, and labs must report positive results to public health authorities. The levels of IgM in a patient's blood begin to rise to detectable levels a few days after infection, while IgG levels become elevated later. Positive results for both IgG and IgM could occur after infection and be indicative of acute or recent infection. The FDA has guided in its "Policy D" that serology tests that are not intended for sole diagnosis do not need only to notify the agency prior to marketing in the US and do not need to come through the EUA process. However, it has also guided that manufacturers claiming a test can be used as a sole diagnostic should come submit an EUA. The test's clinical validation, as noted in the IFU, involved 98 positive serum or plasma samples collected from individuals who tested positive with a RT- PCR method for SARS-CoV-2 infection who exhibited mild or no clinical symptoms and 180 negative serum or plasma samples collected prior to September 2019. Of the 98 positive samples, 91 were positive with IgG or IgM or both. Of the 180 negative samples, 174 were negative. Another 30 samples were collected from hospitalized individuals who were clinically confirmed positive for SARSCoV-2 infection and exhibited severe symptoms. These samples, along with 70 negative serum or plasma samples, were tested with the qSARS-CoV-2 IgG/IgM Rapid Test. Of the 30 positive samples, 29 were positive with IgG or IgM or both. Of the 70 negative samples, 65 were negative. Taken together, the qSARS-CoV-2 IgG/IgM Rapid Test had a 94 percent positive percent agreement and 96 percent negative percent agreement. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Coronavirus COVID-19 Update: Hydroxychloroquine and Other Treatments
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top